China Meheco Group Co.Ltd(600056) again raised the limit, and 11 limit boards have been harvested in the past 14 trading days.
After the cumulative increase of the stock price has been nearly 230%, the risk warning announcement was issued on 6 Shaanxi International Trust Co.Ltd(000563) 21, saying that the acquisition of Pfizer covid-19 oral drug authorization has no significant impact on the company’s recent performance.
In fact, not only China Meheco Group Co.Ltd(600056) , but also the market performance of covid-19 special drugs on March 21 can be called brilliant. Earlier, on March 17, five Chinese enterprises were authorized by Pfizer covid-19 MPP. The agency suggested to continue to pay attention to China’s covid-19 drug R & D and epidemic prevention and control industrial chain.
in addition, according to the performance forecast currently released, the performance of Listed Companies in the pharmaceutical sector generally increased high in 2021. Recently, many fund companies have said that the valuation of the pharmaceutical sector is at a historical low, and the opportunities outweigh the risks
14 day 11 board China Meheco Group Co.Ltd(600056) risk prompt
On March 21, China Meheco Group Co.Ltd(600056) issued a risk warning announcement to give risk warnings on matters related to cooperation with Pfizer China Meheco Group Co.Ltd(600056) said the company signed an agreement with Pfizer Inc in March 9, 2022, and will be responsible for the commercial operation of Pfizer Inc COVID-19 virus treatment PAXLOVID in Chinese mainland market during the agreement period (2022). The product has not yet entered the national medical insurance. If it is included in the national medical insurance, it may have an impact on the sales price. The final use and sales of the product are greatly uncertain due to factors such as epidemic prevention and control, and it is expected that the relevant business scale accounts for a small proportion of the company’s overall business volume, which has no significant impact on the company’s recent operating performance. At present, the company is fully cooperating with the state in the fight against covid-19 epidemic.
It is reported that there are only two covid-19 oral drugs on the market in the world. Among them, Pfizer’s paxlovid is the world’s first oral 3CL protease inhibitor against covid-19 virus. In terms of clinical data, it can reduce the risk of hospitalization and death of 89% covid-19 patients, surpassing another covid-19 oral drug molnupiravir (50%). Meanwhile, paxlovid is also the only covid-19 drug with conditional approval in China. It is expected that the supply of paxlov1 tablets in Japan will increase from US $2.2 billion in the beginning of last year to about US $2.2 billion in the United States, and the supply of paxlov1 tablets in Japan is expected to reach US $2.2 billion.
As early as early March, the industry began to spread the issue of ” China Meheco Group Co.Ltd(600056) won the agency right of Pfizer covid-19″, and China Meheco Group Co.Ltd(600056) won the fourth board from March 2 to March 7.
On the evening of March 9th, China Meheco Group Co.Ltd(600056) announced that the company signed an agreement with Pfizer Inc in March 9th and will be responsible for the commercial operation of Pfizer Inc COVID-19 virus treatment PAXLOVID in Chinese mainland market during the agreement period (2022).
In March 20th, according to the official WeChat official account of China Meheco Group Co.Ltd(600056) , in March 19th, the first batch of COVID-19 virus treatment drugs PAXLOVID, which was co operated by China Meheco Group Co.Ltd(600056) and Pfizer, was transported to the Daxing logistics center of China Meheco Group Co.Ltd(600056) . All goods were closed to the whole process according to the import and export related epidemic prevention requirements, and the relevant work such as acceptance and warehousing had been completed.
According to statistics, in the past 14 trading days (from March 2, 2022 to March 21, 2022), China Meheco Group Co.Ltd(600056) gained a total of 11 limit boards, and the stock price has increased by nearly 230%. As of March 21, the share price closed at 36.59 yuan / share, with a total market value of 39.1 billion yuan.
It is worth noting that this is not the first time that the company issued risk tips. The company previously issued risk tips on March 4, March 14 and March 16 respectively, indicating that the recent rise of the company’s share price may have exceeded the impact of relevant matters on the company’s performance, and there may be irrational investment, prompting investors to pay attention to investment risks, make rational decisions and invest prudently.
According to the announcement on pre reduction of performance in 2021 issued by the company on January 29, 2022, it is expected that the net profit attributable to shareholders of Listed Companies in 2021 will be 300 million yuan to 700 million yuan, a year-on-year decrease of 77% to 47% compared with the same period of last year. The net profit attributable to shareholders of listed companies after deducting non recurring profits and losses was 250 million yuan to 650 million yuan, a year-on-year decrease of 79% to 45% compared with the same period of last year. The specific and accurate financial data shall be subject to the audited annual report of 2021 officially disclosed by the company.
covid-19 special drug sector performs well
Recently, covid-19 special medicine sector has become the strongest outlet of a shares, not only China Meheco Group Co.Ltd(600056) , but also the performance of the whole sector on March 21 Guangdong Zhongsheng Pharmaceutical Co.Ltd(002317) , Jinghua Pharmaceutical Group Co.Ltd(002349) , Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) 3 shares rose by the limit, and Chengda pharmaceutical on GEM rose by more than 14% and Tianjin Chase Sun Pharmaceutical Co.Ltd(300026) by more than 10%.
On March 17, a little earlier, on March 17, the official website of the Geneva pharmaceutical patent pool (MPP) announced that it had signed an agreement with 35 companies on the official website of the Geneva patent pool (MPP) on the official website of the Geneva patent pool (MPP) on March 17, which announced earlier. On March 17, earlier, on March 17, the official website announced that it had signed an agreement with 35 companies to authorize them to copy and produce the API or formulation or preparation and final combination products of the naimatrave, which is an important component of the paxlovid-19 oral drug for pfpfizer’s covid-19. On March 17, the official website of the Geneva patent pool (MPP) announced that it had signed an agreement with 35 companies, and authorized them to sign an agreement and authorize them to copy and produce the API or preparation or preparation of the raw drug or preparation and the final combination products of naimatmatmatrave, the important component of the important component of the paxlovid of the paxlovid-19 oral drug for pfizer-19-19. This medicine, The other four enterprises can produce APIs and preparations at the same time.
In this regard, Zhongtai Securities Co.Ltd(600918) believes that, on the one hand, the market increment of API + preparation may reach 70 billion yuan. It is suggested to pay attention to the performance increment of authorized enterprises and enterprises with the ability and qualification to produce relevant intermediates and advanced processes. On the other hand, it is suggested to pay attention to enterprises with strong technical strength, strong compliance production capacity and ability to undertake spillover orders caused by capacity gap. Pfizer estimates that about 250 million people worldwide need antiviral drugs in 2022, and there is at least a treatment gap of about 130 million. Enterprises with compliant production capacity are likely to benefit from the overflow orders brought by the capacity gap.
China International Capital Corporation Limited(601995) latest research report indicates that the epidemic situation is repeated, and covid-19 related theme investment is still a hot spot.
Recently, the National Audit Office of the State Administration of food and Drug Administration issued the key points of technical review of New Coronavirus antigen detection reagent registration (Trial Implementation), further clarified the relevant registration and evaluation standards of COVID-19 antigen reagents, and the drug administration announced that it would speed up the approval and listing of COVID-19 virus drugs. We suggest continuing to pay attention to China: 1) covid-19 detection, 2) covid-19 therapeutic drugs, 3) investment opportunities related to covid-19 service industry chain.
pharmaceutical sector investment opportunities outweigh risks
According to the performance forecast released at present, the performance of Listed Companies in the pharmaceutical sector is generally high in 2021. As of the evening of March 21, 2022, a total of 113 companies have issued performance letters, of which 89 have increased their net profit in advance, accounting for nearly 80% Chimin Health Management Co.Ltd(603222) net profit increased by 2205% year-on-year, Beijing Hotgen Biotech Co.Ltd(688068) net profit increased by 1857% year-on-year, Tianjin Lisheng Pharmaceutical Co.Ltd(002393) net profit increased by 1313% year-on-year, and the net profit of 17 Companies in 2021 increased by more than 100% year-on-year.
It has been more than half a year since the callback of the high point on July 1, 2021, and the range has exceeded 30%. Looking forward to the future investment in the pharmaceutical sector, many fund companies recently said that the valuation of the pharmaceutical sector is at a historical low, and the opportunities outweigh the risks.
Cathay Pacific Fund said that China’s high-quality medical resources are still in short supply, and most segments have large growth space. From the perspective of performance, there was an epidemic impact from January to February, but according to the announcements of some companies, the operation of leading medical service institutions is improving and the performance maintains a steady growth. Therefore, at the current time point, we are still optimistic about the future performance of the pharmaceutical sector.
Dongfanghong asset management chose to launch the pharmaceutical theme fund against the current market. Jiang Qi, the proposed fund manager, said that the recent withdrawal of the pharmaceutical industry was mainly due to the centralized purchase policy and changes in the external environment, which caused people to worry about the underlying growth logic of the pharmaceutical industry. At the same time, the institutional allocation was crowded, which led to the killing of the valuation of the sector. At present, the adjustment of medical policy has tended to be gentle. CXO, services and other pharmaceutical core racetracks have a significant decline in the higher valuation, and the risk is released to a great extent. At the same time, the congestion of fund positions has been greatly alleviated, and has entered a layout period in which in-depth research can bring value. In terms of investors’ interests, now may be a good allocation opportunity, which is also more favorable for fund position building.
On the segment track, Qiao Haiying, deputy director of the public investment department of Oriental alpha fund, said in an interview with the Chinese reporter of the securities firm that the segment market determines the ceiling and the competitive advantage determines the profit margin. We are more optimistic about the three high boom development directions of innovation and upgrading, manufacturing upgrading and consumption upgrading, and focus on the innovative drug (machinery) industry chain, medical services, biological products and so on.
